Publications
Advances in metal-organic frameworks for cardiovascular therapy: from structural design to preclinical applications;
Ge, X, Liu, Y, Zhao, X, Nafady, A, Bhattacharya, G, Mai, J, Al-Enizi, AM, Pettigrew, RI & Ma, S 2025, , Coordination Chemistry Reviews, vol. 544, 216971. https://doi.org/10.1016/j.ccr.2025.216971
O-GlcNAcylation promotes angiogenic transdifferentiation to reverse vascular ischemia;
Li, S, Lu, AJ, Nagueh, ES, Li, Y, Graber, M, Carter, KN, Morales, E, Kriss, CL, Chen, K, Liu, J, Wang, G, Cooke, JP & Lai, L 2025, , Nature Cardiovascular Research, vol. 4, no. 7, pp. 904-920. https://doi.org/10.1038/s44161-025-00673-7
Circular RNA Telomerase Reverses Endothelial Senescence in Progeria;
Qin, W, Castillo, KD, Li, H, Nguyen, TKC, Kiss, DL, Cooke, JP & Mojiri, A 2025, , Aging Cell, vol. 24, no. 6, e70021. https://doi.org/10.1111/acel.70021
A visual–omics foundation model to bridge histopathology with spatial transcriptomics;
Chen, W, Zhang, P, Tran, TN, Xiao, Y, Li, S, Shah, VV, Cheng, H, Brannan, KW, Youker, K, Lai, L, Fang, L, Yang, Y, Le, NT, Abe, JI, Chen, SH, Ma, Q, Chen, K, Song, Q, Cooke, JP & Wang, G 2025, , Nature Methods, vol. 22, no. 7, pp. 1568-1582. https://doi.org/10.1038/s41592-025-02707-1
RNA therapeutics in cardiovascular medicine;
Damase, TR & Cooke, JP 2025, , Current Opinion in Cardiology, vol. 40, no. 3, pp. 139-149. https://doi.org/10.1097/HCO.0000000000001210
From the Masters: How RNA drugs will transform vascular medicine;
Cooke, JP 2025, , Vascular Medicine (United Kingdom), vol. 30, no. 2, pp. 120-123. https://doi.org/10.1177/1358863X251323275
The impact of T7 RNA polymerase class II pause sites on mRNA therapeutics;
Li, LH, Wang, X, Yan, Q, Gateway, CG, Van Meter, B, Damase, T, Liang, Y, Morales, E, Domingues Bueno, MT, McRae, EKS & Cooke, JP 2025, , Cardiology Plus, vol. 10, no. 2, pp. 99-109. https://doi.org/10.1097/CP9.0000000000000123
The rapidly emerging field of RNA therapies for cardiovascular disease;
Cooke, JP 2025, , Cardiology Plus, vol. 10, no. 2, pp. 79-82. https://doi.org/10.1097/CP9.0000000000000121
Modulation of cell fate by shock wave therapy in ischaemic heart disease;
Graber, M, Gollmann-Tepeköylü, C, Schweiger, V, Hirsch, J, Pölzl, L, Nägele, F, Lener, D, Hackl, H, Sopper, S, Kirchmair, E, Mair, S, Voelkl, J, Plattner, C, Eichin, F, Trajanoski, Z, Krogsdam, A, Eder, J, Fiegl, M, Hau, D, Tancevski, I, Grimm, M, Cooke, JP & Holfeld, J 2025, , European Heart Journal Open, vol. 5, no. 2, oeaf011. https://doi.org/10.1093/ehjopen/oeaf011
Reevaluating Anti-Inflammatory Therapy: Targeting Senescence to Balance Anti-Cancer Efficacy and Vascular Disease;
Casso-Chapa, B, Vazquez González, NA, Le, NT, Palaskas, NL, Nead, KT, Eutsey, LP, Samanthapudi, VSK, Osborn, AM, Lee, J, Mejia, G, Hoang, O, Lin, SH, Deswal, A, Herrmann, J, Wang, G, Kirkland, JL, Krishnan, S, Wehrens, XHT, Chini, EN, Yusuf, SW, Iliescu, CA, Jain, A, Burks, JK, Seeley, E, Lorenzi, PL, Chau, KM, Ostos Mendoza, KC, Grumbach, IM, Brookes, PS, Hanssen, NMJ, De Winther, MPJ, Yvan-Charvet, L, Kotla, S, Schadler, K & Abe, JI 2025, , Arteriosclerosis, Thrombosis, and Vascular Biology, vol. 45, no. 3, pp. 372-385. https://doi.org/10.1161/ATVBAHA.124.319870